Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 29 30 31 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
IROA Technologies–Bruker Corp: mass spectrometer, 201310 supply existent IROA uses Bruker MS for metabolomics research 2013-10-31
Merck (DE)–Max Planck: drug discovery services, 201310– collab 5y strategic partnership of Merck Serono with Lead Discovery Center GmbH 2013-10-31
Ako med–Curetis: Unyvero system, 201310 distribution existent Ako med doo is distributor in countries of former Yugoslavia for system + cartridges 2013-10-30
BioLine (RU)–Curetis: Unyvero system, 201310 distribution existent BioLine LLC is Russian distribution partner for system + cartridges 2013-10-30
Sanofi–Genedata: bioinformatics, 201310– supply Genedata Biologics data management platform will be used for biologcics sreening 2013-10-30
BioChain–Epigenomics: molecular diagnostics, 201310– broad strategic collaboration expanding prior license agreement for China 2013-10-28
Cell Signaling Technology–RainDance: RainDrop Digital PCR System, 201310– distribution by BIOKÉ in Germany + Benelux 2013-10-28
Epigenomics–BioChain: investment, 201310 acquisition €0.94m ($1.3m) of 217.9k new shares as part of strategic collaboration 2013-10-28
Formycon–SEVERAL: investment, 201310–201312 capital increase €9.4m 1.257m new common shares €7.5/share to existing shareholders 2013-10-28
Genetrix (ES)–SEVERAL: investment, 201310 rights offering + private placement of Sygnis AG €2.7m with 1.02m new shares €2.65/share 2013-10-28
Hana Pharmaceuticals–Paion: remimazolam, 201310– license excl €1m upfront + €2m milestones + 10% royalties for dev + manuf + commerc in Korea 2013-10-28
Biotest–SEVERAL: credit, 201310– placing of €210m notes in different tranches to more than 70 investors 2013-10-24
Merck (DE)–Polyplus-transfection: transfection reagents, 201310– license + supply agreem €na for PEI-based transfection reagents incl PEIpro 2013-10-24
Polyplus-transfection–Image Box: public relations, 201310 service existent by Image Box PR 2013-10-24
Celesio–McKesson: investment, 201310– acquisition €6.1b with acqu of 50.01% shares from Haniel + cash tender offer for all remaining shares €23/share 2013-10-23
Chem Tech Research–Apeptico: proteomic database, 201310– license to Pepbase therapeutic protein database for C-TRI 2013-10-23
F-Star Alpha–F-Star: cancer drugs, 201310– license excl to FS102 + Fcab + mAb2 technologies against up to 22 cancer targets 2013-10-23
F-Star Alpha–SEVERAL: investment, 201401 financing round Series A €9.4m incl Atlas Venture + Aescap + TVM + SR One + MP Healthcare + MS Ventures 2013-10-23
Boehringer–Beactica: drug discovery services, 201310– collab expansion €na fragment-based drug discovery services for oncology-relevant kinases 2013-10-22
Finox–SEVERAL: investment, 201310 capital increase CHF22m incl CHF12m from majority shareholder Willy Michel + CHF10m from BV Group 2013-10-22
Heraeus–Curetis: molecular diagnostics, 201310 collab existent co-developm + co-marketing of Unyvero i60 ITI application 2013-10-22
Roche–Samsung: biopharmaceuticals, 201310– supply €na long-term strategic contract manufacturing agreem with Samsung BioLogics 2013-10-22
Zivak Technologies–Tecan: automated liquid handling, 201310 supply Cavro Omni Robot for use with clinical Dx HPLC + LC-MSMS systems 2013-10-22
AstraZeneca–Evotec: kidney disease drugs, 201310– license + collab agreem €na giving AZ access to selected series of molecules to treat CKD 2013-10-21
Clovis Oncology–Qiagen: molecular companion diagnostics, 201310– collab developm of therascreen EGFR RGQ PCR Kit for CO-1686 2013-10-21
Mérieux–MC Services: public relations, 201310 service existent for Transgene SA 2013-10-21
Austria (govt)–Biocom: publishing, 201310 supply service with regard to Vienna Life Science Report 2013/14 to LISAvienna by Biocom 2013-10-17
Biodesy–Roche: investment, 201310 financing round Series A totalling $15m incl Roche Venture Fund 2013-10-17
Biodesy–SEVERAL: investment, 201310 financing round Series A $15m from 5AM Ventures + Pfizer Venture Investments + Roche Venture Fund 2013-10-17
Boehringer–Vector Capital: drug discovery s/w, 201310– supply Certara D360 as drug discovery platform in Ridgefield + Biberach + Vienna 2013-10-17
Suzhou SJ Biomaterials–Scienion: print/spotting technology, 201310– distribution of Scienion products in China by Suzhou SJ Biomaterials Co Ltd 2013-10-17
Sygnature Discovery–Proteros: drug discovery services, 201310– collab strategic alliance to offer integrated services incl X-ray structure analysis 2013-10-17
Merck (DE)–Firefly BioWorks: miRNA research assays, 201310– distribution ww of SmartRNAPlex assay by EMD Millipore 2013-10-16
Photonics Healthcare–Bavaria (govt): investment, 201310 1st financing round led by HTGF + Bayern Kapital 2013-10-16
Photonics Healthcare–High-Tech Gründerfonds: investment, 201310 1st financing round led by HTGF + Bayern Kapital 2013-10-16
Photonics Healthcare–SEVERAL: investment, 201310 1st financing round led by HTGF + Bayern Kapital 2013-10-16
AstraZeneca–Auven Therapeutics: antibody-drug conjugates, 201310– collab of ADC Therapeutics and MedImmune which acquired Spirogen 2013-10-15
Auven Therapeutics–AstraZeneca: investment, 201310 acquisition 100% of Spirogen Ltd for $200m upfront + $240 milestones by MedImmune 2013-10-15
Auven Therapeutics–AstraZeneca: investment, 201310 investment $20m in ADC Therapeutics by MedImmune matched by majority shareholder Auven Therapeutics 2013-10-15
CV genes-at-target project–EU (govt): grant, 2013– FP7 grant €5.75m to investigate genomic risk loci for CAD + stroke 2013-10-15
CV genes-at-target project–Evotec: genomic drug target discovery, 2013– collab European ScreeningPort is partner in FP7 project 2013-10-15
CV genes-at-target project–Genedata: genomic drug target discovery, 2013– collab Genedata is partner in FP7 project 2013-10-15
CV genes-at-target project–Univ Lübeck: genomic drug target discovery, 2013– collab Univ of Lübeck is partner in FP7 project 2013-10-15
Immatics–SEVERAL: investment, 201310 financing round Series D 1st tranche €12m of €34m round Hopp + Strüngmann + Wellington Partners + MIG Funds 2013-10-15
Bayer–BioInvent: antibody library, 201310 license €na extension + broadening to n-CoDeR libraries for development of therapeutic antibodies 2013-10-14
Novartis–ImmunoGen: ADC technology, 201310– license to use technology against a cancer target under collab agreem from 2010 2013-10-11
Cytos Biotechnology–SEVERAL: investment, 201310–201311 capital increase CHF24.3m 8.1m shares CHF3/share to Abingworth + Amgen + venBio + Aisling et al 2013-10-10
Bayer–RWTH Aachen: bioinformatics, 201310– collab founding of Joint Research Center on Computational Biomedicine by BTS + RWTH 2013-10-09
Bayer–Sysmex: molecular companion diagnostics, 201310– collab master agreem for developm of blood-based CDx for cancer drugs by Sysmex Inostics 2013-10-09
Sartorius–PERSON: investment, 201310 existent family of the late Horst Satorius owns 50.09% bound by last will of Horst Satorius 2013-10-09
Schott–Sony: slides, 201310 collab developm + marketing of glass-plastic hybrid cell imaging slide 2013-10-07
JnJ–CureVac: vaccine technology, 201310– collab + license €na use of RNActive technology for developm of mRNA-based influenza vaccine with Crucell 2013-10-03
Merus–Akampion: public relations, 201310 service existent by Akampion 2013-10-03
Acino–Avista Capital: investment, 201310– public tender offer CHF398m with CHF115/share by Avista Capital Partners + Nordic Capital 2013-10-02
Acino–Nordic Capital: investment, 201310– public tender offer CHF398m with CHF115/share by Avista Capital Partners + Nordic Capital 2013-10-02
Acino–SEVERAL: investment, 201310– public tender offer CHF398m with CHF115/share by Avista Capital Partners + Nordic Capital 2013-10-02
Polymedco–Epigenomics: molecular diagnostics, 201310– collab joint commercialisation of Epi proColon test in North America 2013-10-02
Findeisen Laborbedarf–Omnilab (DE): investment, 201310 acquisition of Findeisen Laborbedarf GmbH by Omnilab-Laborzentrum GmbH & Co KG 2013-10-01
Innovative Medicines Initiative–EU (govt): grant, 201310– funding €8m for GETREAL project by IMI of €16.3m total cost 2013-10-01
Labfolder–SEVERAL: investment, 201310 seed financing round € high 6-digit incl Vogel Ventures + VC Fonds Technologie Berlin 2013-10-01
SYMPATH project–EU (govt): grant, 201310–201709 FP7 grant €5.89m out of total budget €7.69m to develop Parkinson vaccine 2013-10-01
Dualsystems Biotech–SEVERAL: investment, 201309 financing round Series C from existing + new investors 2013-09-30
Roche–Activiomics: mass spectrometry services, 201309 supply services recent partner is Genentech 2013-09-30
Analytik Jena–Endress+Hauser: investment, 201309–201603 mandatory offer for remaining 52.67% of shares for €13.75/share 2013-09-27
Analytik Jena–PERSON: investment, 201309 existent founder + CEO Klaus Berka owns 9.93% 2013-09-27
Panasonic–Kohlberg Kravis Roberts: investment, 201309– acquisition $1.67b of 80% share in Panasonic Healthcare Co Ltd by KKR 2013-09-27
Merck (DE)–Ablynx: Nanobodies, 201309– collab co-discovery + co-developm Nanobodies extension Merck Serono 2013-09-26
Panoptes Pharma–4SC: investment, 201309 4SC Discovery receives 24.9% share in Panoptics as part of license for PP-001 2013-09-26
Panoptes Pharma–4SC: PP-001, 201309– license for inflammatory eye diseases against 24.9% share in Panoptes plus milestones + royalties 2013-09-26
Panoptes Pharma–SEVERAL: investment, 201309 seed financing round €1.2m from aws-Life Science Austria + private investors 2013-09-26
Indivumed–Sysmex: investment, 201309–201310 acquisition of 100% of Inostics GmbH + its subsidiary Inostics Inc by Sysmex Corp 2013-09-25
Roche–Pacific Biosciences: SMRT technology, 201309– collab ww excl $35m upfront developm + manufacture products for clinical use for Roche Diagnostics 2013-09-25
Partec–Sysmex: investment, 201309 acquisition of Partec GmbH by Sysmex Corp 2013-09-24
Myelo Therapeutics–Berlin (govt): investment, 201309 financing round Series A incl VC Fonds Technologie Berlin 2013-09-23
Myelo Therapeutics–Eckert Wagniskapital: investment, 201309 financing round Series A incl Eckert Wagniskapital und Frühphasenfinanzierung GmbH 2013-09-23
Myelo Therapeutics–JSC Valenta Pharmaceuticals: investment, 201309 financing round Series A incl JSC Valenta Pharmaceuticals 2013-09-23
Myelo Therapeutics–SEVERAL: investment, 201309 financing round Series A from VC Fonds Technologie Berlin + Eckert Wagniskapital + JSC Valenta 2013-09-23
Verenium–BASF: investment, 201309–201310 acquisition $52m cash tender offer $4/share by BASF Corporation 2013-09-20
Bruker–Philips: magnetic particle imaging, 201309 collab co-developm + co-marketing of preclinical MPI system 2013-09-19
Kyowa Hakko Kirin–Activiomics: mass spectrometry services, 201309– supply extension research services w TIQUAS technology within BioFocus partnership 2013-09-19
IKFE–Columbia Healthcare Services: investment, 201309 acquisition 100% of IKFE Services GmbH which continues business of bankrupt IKFE Institut 2013-09-18
MorphoSys–SEVERAL: investment, 201309 private placement €84m with 1.5m new shares €55.76/share to institutional investors 2013-09-18
Evonik–Genedata: bioinformatics, 201309– collab expansion use of integrated Genedata offering incl Genedata Selector 2013-09-17
Microstim–SEVERAL: investment, 201309 financing round €500k MVP + HTGF + Fides Finanz-Invest 2013-09-17
Affimed–MC Services: public relations, 201309 service existent for Affimed Therapeutics AG 2013-09-16
Bruker Corp–Siscapa: SISCAPA assay technology, 201309– collab extension developm SISCAPA-MALDI workflows + installation in demo facility 2013-09-16
Rhön-Klinikum–Fresenius: investment, 201309– acquisition of 43 German hospitals for €3.07b by Fresenius Helios ANNOUNCED 2013-09-13
Evotec–Harvard Univ: drug discovery, 201309– collab €na drug discovery for ALS using iPS cells with HSCI 2013-09-12
Prairie Technologies–Bruker Corp: investment, 201309 acquisition by Bruker 2013-09-12
Bayer–MIT: personalised cancer drugs, 201309– collab 5y discovery + development using oncogenomics with Broad Institute 2013-09-10
Bruker Corp–Peak Scientific: gas generator, 201309– supply OEM excl for Bruker GC-MS range + supporting for LC-MS 2013-09-10
Roche–Inovio: therapeutic vaccines, 201310– license ww excl $10m upfront + $412.5m milestones for INO-5150 + INO-1080 + use of Cellectra technology 2013-09-10
Neurodyn–Galantos: galantamine, 201309 acquisition of all assets related to Memogain® formulation of galantamine by Neurodyn 2013-09-09
ArcherDX–Enzymatics: investment, 201309 acquisition up to $50m in cash + equity + milestones 2013-09-06
Novartis–Regenerex: cell therapy, 201309– global license + research collab for use of hematopoietic stem-cell based FCRx platform 2013-09-06
Wilex–Nuclea Biotechnologies: investment, 201309 acquisition 100% of Wilex Inc by Nuclea w repayment $2.5m interfirm loan + $2.5m services + royalties 2013-09-06
Debiopharm–Go To Market: business consulting, 201309– supply service identification of early-stage in-licensing opportunities on US West Coast 2013-09-05
Piqur Therapeutics–SEVERAL: investment, 201309 private placement (third seed financing round) 2013-09-05
Analytik Jena–Endress+Hauser: investment, 201309 capital increase €24.4m incl Endress+Hauser with resulting direct + indirect 47.33% share for E+H 2013-09-04
Analytik Jena–SEVERAL: investment, 201309 capital increase €24.4m €23.4m net 1.95m new shares €12.5/share exlusively to existent shareholders 2013-09-04
next pagenext page 1 2 3 ... 29 30 31 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top